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Abstract 
Introduction Ca2+/calmodulin dependent protein kinase II (CaMKII) is a central mediator of Ca2+-
induced signalling in the heart and regulates both normal cardiac physiology and pathology. 
Sunitinib malate is an oral Type I tyrosine kinase inhibitor (TKI) known to inhibit more than 50 
kinases, with anti-angiogenic and anti-proliferative effects affiliated with off-target cardiotoxicity. 
Previous work has shown that chronic sunitinib treatment significantly increases CaMKII expression 
and activity and this correlates with significant cardiac dysfunction in vivo.1 Mitochondrial 
dysfunction, mediated by increased mitochondrial Ca2+ and resultant mitochondrial ROS production, 
has been proposed as an underlying mechanism for TKI-induced cardiotoxicity in cardiomyocytes.2 
However, little is known of how TKIs may affect the non-contractile cells of the heart. Here, we have 
investigated whether sunitinib treatment increases mitochondrial ROS production in cardiac 
fibroblasts (CF) and whether CaMKII may play a role in this potential cardiotoxic mechanism. 
Methods CF were isolated from adult Sprague-Dawley rats (male, 250–350 g, n=8) via bulk 
collagenase digestion and were maintained in culture before treatment with sunitinib (Cayman 
Chemical Company, Michigan, USA) (1–10µM) for 16 hours in the presence of serum (DMEM 
supplemented with 20% FBS). Mitochondrial superoxide production was assessed using MitoSOX 
Red (ThermoFisher Scientific, UK). CF were pre-treated with 5µM KN-93 (2 hours) Sigma-Aldrich, UK) 
to inhibit CaMKII before the addition of 10µM sunitinib for 16 hours. MitoSOX Red analysis was then 
repeated as before. Data are presented as mean values ± S.E.M of n observations, where n 
represents the number of samples. Comparisons were assessed by one-way ANOVA with post hoc 
Dunnett’s test. 
Results MitoSOX fluorescence imaging revealed a significant increase in mitochondrial superoxide 
production in sunitinib treated CF (144.6±1.1 vs 526.2±24.0 vs 178.8±4.6 relative fluorescent units; 
control vs 10µM sunitinib vs 10µM antimycin A, n=3, p<0.05). However, KN-93 pre-treatment 
significantly reduced mitochondrial ROS production in sunitinib treated CF (440.2±0.6 vs 680.5±5.6 
vs 576.1±11.4 relative fluorescent units; control vs 10µM sunitinib vs 10µM sunitinib + 5µM KN-93, 
n=3, p<0.05). 
Conclusion Sunitinib treatment increases mitochondrial superoxide production in CF, supporting a 
previously proposed TKI-induced cardiotoxic mechanism mediated by mitochondrial dysfunction. 
This cardiotoxic mechanism may be mediated by CaMKII (activated via oxidation), although further 
work is required to corroborate this. Future work will determine the effect this mechanism has on 
mitochondrial function and establish whether targeted CaMKII inhibition can reduce/reverse TKI-
induced cardiotoxic effects. 
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